Tesamorelin for Visceral Fat: What the Research Actually Shows

Peptide Profiles — 2026-05-14

Of all the body-composition peptides on the market, tesamorelin is the only one with an FDA-approved indication specifically for visceral fat reduction. That distinction matters: visceral adipose tissue (VAT) — the metabolically active fat surrounding abdominal organs — is the fat depot most strongly associated with cardiometabolic risk. Tesamorelin is the most-studied peptide in that specific axis.

Researcher special: code WELCOME at checkout unlocks 35% off Tesamorelin 10mg, the Metabolic Stack, the Shredder family, and bacteriostatic water. Every vial ships with a batch-matched COA at 99%+ HPLC purity.

What Tesamorelin Is

Tesamorelin is a synthetic 44-amino-acid analog of growth hormone-releasing hormone (GHRH). Structurally, it's GHRH(1–44) with an N-terminal trans-3-hexenoic-acid modification that protects it from dipeptidyl peptidase-4 (DPP-4) degradation, extending its half-life enough to make once-daily subcutaneous dosing practical.

Mechanistically, tesamorelin acts on the pituitary GHRH receptor to stimulate pulsatile release of endogenous growth hormone (GH). Higher GH levels drive hepatic IGF-1 production, increased lipolysis, and — most importantly for this research line — a preferential reduction in visceral adipose tissue.

For the broader tesamorelin profile, see our tesamorelin research overview.

The FDA Approval and Why It Matters for Research

Tesamorelin received FDA approval in 2010 (under the trade name Egrifta) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. That patient population is characterized by accumulation of visceral fat as a side effect of antiretroviral therapy, and tesamorelin was the only agent shown to specifically and reproducibly reduce VAT in that group.

The pivotal trials (Falutz et al., NEJM 2007; subsequent multi-center Phase 3 trials) established the core finding: tesamorelin reduces VAT by approximately 15–18% over 26 weeks, with the effect maintained over 52 weeks of continued treatment. Discontinuation reverses the effect within months — VAT reaccumulates once GH levels normalize.

That's the dataset that anchors all subsequent visceral-fat research with tesamorelin.

The Visceral Fat Mechanism

GH preferentially lipolyzes visceral fat for several reasons:

1. Higher GH receptor density — visceral adipocytes express more GH receptors than subcutaneous adipocytes.
2. Higher hormone-sensitive lipase (HSL) activity — GH activation of HSL is more pronounced in visceral fat.
3. Portal drainage — fatty acids liberated from visceral fat drain into the portal vein, where they're preferentially oxidized in the liver rather than re-esterified peripherally.
4. Lower local IGF-1 antagonism — peripheral IGF-1 feedback dampens GH effects more in subcutaneous than visceral depots.

The net result: when GH levels rise via tesamorelin-driven pulsatile release, visceral fat is mobilized faster and to a greater extent than subcutaneous fat. This is why the body-composition signature of tesamorelin is distinctive — researchers see a measurable waist-circumference reduction with relatively modest total weight change.

What the Body-Composition Data Looks Like

Across the pivotal trials and follow-up studies, the consistent pattern at the standard 2 mg/day SC dose:

The point worth emphasizing: tesamorelin is not a weight-loss agent in the GP-class sense. Total weight change is small. What changes is the *distribution* of fat — visceral down, subcutaneous mostly unchanged. For metabolic research where VAT is the primary endpoint, this specificity is the entire point.

For comparison context with the GP-class, see reta vs tesamorelin.

Beyond HIV Lipodystrophy: Wider Research Use

The HIV-lipodystrophy indication is what got tesamorelin approved, but the underlying mechanism is not HIV-specific. Subsequent studies have explored tesamorelin in:

NAFLD / MASLD Stanley et al. (Lancet HIV, 2019) showed tesamorelin reduced hepatic fat fraction in HIV patients with NAFLD, with about a 37% relative reduction in liver fat over 12 months. The signal is mechanism-consistent: visceral fat reduction and improved hepatic GH signaling both contribute to liver-fat reduction. Subsequent research has extended the model to non-HIV NAFLD populations.

General abdominal-fat research Smaller studies have tested tesamorelin in non-HIV adults with abdominal obesity. Effects are directionally similar but smaller in magnitude than in the HIV-lipodystrophy population — VAT is reduced, but not as dramatically.

Cognitive function Baker et al. (Archives of Neurology, 2012) reported that tesamorelin improved cognitive performance in older adults, possibly via downstream GH/IGF-1 effects on brain metabolism. This is an active research direction adjacent to the body-composition use case.

Combination with metabolic peptides Research stacking patterns combine tesamorelin with MOTS-c (substrate utilization) and with GP-class peptides for appetite suppression. The Shredder Stack family is designed around exactly this combination logic.

Dosing in Research Protocols

The standard tesamorelin dose used across the trial program is 2 mg subcutaneously, once daily, typically administered in the evening to align with the natural overnight GH pulse. Most VAT-reduction endpoints take 12–26 weeks to fully develop.

Practical research handling: - 10mg vial — standard; reconstitute with 2 mL bac water for 5 mg/mL (= 40 units = 2 mg per dose on a U-100 syringe) - Cycle length — 12 weeks minimum for VAT endpoints; 26 weeks for liver-fat endpoints - Storage — lyophilized at −20°C; reconstituted vials refrigerated at 2–8°C and used within ~28 days - Site rotation — abdominal SC sites; rotate to avoid local lipoatrophy

For dosing detail, see tesamorelin dosing and cycling.

Side-Effect Profile in Research

The reported side-effect profile from the trial program:

• Injection-site reactions — most common; mild and transient
• Arthralgia / fluid retention — class effect of elevated GH; usually mild
• Glucose elevation — small but measurable rise in fasting glucose; monitored in diabetic models
• IGF-1 elevation — into upper-normal range at therapeutic doses; rare elevations above the reference range

The glucose effect is the one most relevant to metabolic research design. Tesamorelin will modestly raise fasting glucose and HbA1c — the magnitude is small but reproducible, and researchers running concurrent glucose-tolerance endpoints should account for it.

Where Tesamorelin Fits in the Top-Selling Peptides

Among the top-selling peptides in 2026 research catalogs, tesamorelin is the most specific tool for visceral-fat work. The GP-class peptides (reta, sema, triz) drive larger total-weight changes but are less VAT-selective. IGF-1 LR3 drives muscle anabolism, not fat distribution. CJC/Ipamorelin drives GH pulsatility through a different mechanism and is less VAT-selective than tesamorelin in head-to-head comparisons.

For an overview of the broader peptide landscape, see top research peptides of 2026.

Practical Sourcing

For visceral-fat research with tesamorelin: - Tesamorelin 10mg vial — 5 doses at 2mg, or ~2 weeks at standard daily protocol - Bacteriostatic water 10mL — multi-vial reconstitution - U-100 insulin syringes — for accurate 40-unit dosing

Code WELCOME at checkout unlocks 35% off Tesamorelin 10mg, the Metabolic Stack, the Shredder Stack family (with MOTS-c and Reta), and bacteriostatic water. Every vial ships with a batch-matched COA showing 99%+ HPLC purity, US-based handling, and the sequence-verified identity that matters when your endpoint is CT-measured VAT change over a 26-week study.

Disclaimer: All information presented in this article is for educational and informational purposes only. Platinum Biolabs does not promote or endorse the use of peptides for human consumption. All products sold by Platinum Biolabs are intended strictly for laboratory and research use only. Consult a qualified healthcare professional before making any health-related decisions.